AUA

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

A phase 3 trial reveals a combination therapy for premature ejaculation significantly enhances treatment outcomes.

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.

"The decision for which laser to use in your institution should be left up to the urologist and the hospital system," says Margaret A. Knoedler, MD.

The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.

"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.

New research links higher drinking water contaminants to increased kidney stone risk.

“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.

A groundbreaking male contraceptive shows promising safety results, offering a reversible option for couples seeking effective birth control.

Treatment with TARA-002 was associated with a 100% high-grade CR at any time in BCG-unresponsive participants.

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.

View slated interviews with experts as well as insights from urologists on what to watch for.

Take a look through several of the notable phase 3 trials in progress that will be spotlighted at AUA 2025.

We preview several noteworthy P2 presentations in the urologic oncology space.

“At the Advocacy Summit earlier this spring, 2 of the 3 leave-behind documents that outlined specific issues related to urology priorities were directly informed by information from the Census,” says Matthew Nielsen, MD, MS, FACS.

“The way to move the organization forward is to listen to learn, not to win,” says J. Stuart Wolf, Jr., MD, FACS.

Raveen Syan, MD, highlights 2 sessions that she took part in during the 2024 AUA Annual Meeting in San Antonio, Texas on urodynamics in the context of the VALUE trial and the new wave of percutaneous tibial nerve stimulation devices.

"The other was that we found that about half of the patients in the CIS cohort and two-thirds of those in the Ta/T1 or papillary cohort had bladder preservation, meaning they were able to avoid cystectomy," says Vikram M. Narayan, MD.

“When we looked at the risk of bleeding and takeback for fulguration, the reported rate was 0.46%. Less than 1% of patients had any significant bleeding,” says Dean S. Elterman, MD, MSc, FRCSC.

"In our commercial all-comers cohort of patients undergoing Aquablation, efficacy was similar to and safety was improved compared to the WATER I and WATER II clinical trials," says Shawn H. Marhamati, MD, MS.

"So, there's a lot of evidence to point to the androgen receptor being an important player in at least developing this disease," says Edward M. Messing, MD.

“The 2018 AUA guidelines for testosterone therapy that were co-chaired by Dr. John P. Mulhall say that we have an absence or a paucity of data on using testosterone therapy on active surveillance,” says Helen L. Bernie, DO, MPH.

"But more excitingly, as early as 9 months, even though they were small numbers, the comparison between BCG and Anktiva vs BCG alone showed a statistical significance in the duration of ongoing complete response," says Patrick Soon-Shiong, MD.

"We're doing a lot of active surveillance, and it's good to know that most of these people are getting the appropriate care that they should receive," says Yuzhi (Katherine) Wang, MD.

“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.

Patients who received PUL experienced a greater reduction in inference regarding outdoor entertainment and community activities at 1 month vs WVTT.

“Also, the technique lends itself really nicely to these, what we call posterior ball-valve tumors, which are these tumors that sit behind the renal hilum, behind the blood vessels on the posterior side of the kidney,” says Alexander Kutikov, MD, FACS.

There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.